Abbott Hosts Conference Call for Fourth-Quarter Earnings
Werte in diesem Artikel
ABBOTT PARK, Ill., Jan. 2, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens.
The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Central time (9:30 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
View original content:https://www.prnewswire.com/news-releases/abbott-hosts-conference-call-for-fourth-quarter-earnings-302337311.html
SOURCE Abbott
Ausgewählte Hebelprodukte auf Abbott Laboratories
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Abbott Laboratories
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Abbott Laboratories
Analysen zu Abbott Laboratories
Datum | Rating | Analyst | |
---|---|---|---|
27.08.2020 | Abbott Laboratories Sell | Goldman Sachs Group Inc. | |
16.10.2018 | Abbott Laboratories Overweight | Barclays Capital | |
25.01.2018 | Abbott Laboratories Buy | Stifel, Nicolaus & Co., Inc. | |
15.12.2017 | Abbott Laboratories Outperform | BMO Capital Markets | |
19.10.2017 | Abbott Laboratories Buy | Stifel, Nicolaus & Co., Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
16.10.2018 | Abbott Laboratories Overweight | Barclays Capital | |
25.01.2018 | Abbott Laboratories Buy | Stifel, Nicolaus & Co., Inc. | |
15.12.2017 | Abbott Laboratories Outperform | BMO Capital Markets | |
19.10.2017 | Abbott Laboratories Buy | Stifel, Nicolaus & Co., Inc. | |
19.10.2017 | Abbott Laboratories Outperform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
23.07.2015 | Abbott Laboratories Equal Weight | Barclays Capital | |
27.03.2015 | Abbott Laboratories Equal Weight | Barclays Capital | |
30.01.2015 | Abbott Laboratories Equal Weight | Barclays Capital | |
07.01.2013 | Abbott Laboratories halten | Deutsche Bank Securities | |
29.11.2012 | Abbott Laboratories neutral | Sarasin Research |
Datum | Rating | Analyst | |
---|---|---|---|
27.08.2020 | Abbott Laboratories Sell | Goldman Sachs Group Inc. | |
25.10.2011 | Abbott Laboratories sell | Citigroup Corp. | |
05.10.2011 | Abbott Laboratories sell | Citigroup Corp. | |
22.11.2006 | Advanced Medical Optics sell | Citigroup | |
11.09.2006 | Abbott Laboratories reduce | UBS |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Abbott Laboratories nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen